Transgene
Transgene
TNG
EURONEXT
0.69
EUR
0.00%
About
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B.
The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases.
The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 40.2K |
| Three Month Average Volume | 525.9K |
| High Low | |
| Fifty-Two Week High | 1.86 EUR |
| Fifty-Two Week Low | 0.985 EUR |
| Fifty-Two Week High Date | 13 Sep 2023 |
| Fifty-Two Week Low Date | 15 Aug 2024 |
| Price and Volume | |
| Current Price | 1.12 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.68% |
| Thirteen Week Relative Price Change | -10.30% |
| Twenty-Six Week Relative Price Change | 9.94% |
| Fifty-Two Week Relative Price Change | -39.20% |
| Year-to-Date Relative Price Change | -19.35% |
| Price Change | |
| One Day Price Change | -0.88% |
| Thirteen Week Price Change | -14.24% |
| Twenty-Six Week Price Change | 5.66% |
| Five Day Price Change | 6.06% |
| Fifty-Two Week Price Change | -36.29% |
| Year-to-Date Price Change | -18.25% |
| Month-to-Date Price Change | -0.88% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.15527 EUR |
| Book Value Per Share (Most Recent Quarter) | 0.15527 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.15447 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.15447 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.28187 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.07589 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.07589 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | 0 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.22197 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.22272 EUR |
| Normalized (Last Fiscal Year) | -0.22162 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.22197 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.22272 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.22197 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.22272 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.1558 EUR |
| Cash Per Share (Most Recent Quarter) | 0.1558 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.20554 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.20548 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.37119 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -243 |
| Cash Flow Revenue (Trailing Twelve Months) | -489 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -292.48% |
| Pretax Margin (Last Fiscal Year) | -292.48% |
| Pretax Margin (5 Year) | -193.24% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -393.59% |
| Operating Margin (Trailing Twelve Months) | -393.59% |
| Operating Margin (5 Year) | -232.02% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -292.48% |
| Net Profit Margin (Trailing Twelve Months) | -292.48% |
| Net Profit Margin (5 Year) | -193.24% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -23.03% |
| Tangible Book Value (5 Year) | -15.72% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -25.24% |
| Revenue Growth (3 Year) | 1.51% |
| Revenue Change (Trailing Twelve Months) | -23.68% |
| Revenue Per Share Growth | -7.31% |
| Revenue Growth (5 Year) | -6.51% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 14.44% |
| Total Debt (5 Year) | -44.26% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 63.76% |
| EPS Change (Trailing Twelve Months) | 32.41% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 10 |
| Price to Tangible Book (Most Recent Quarter) | 10 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,459,000 |
| Net Debt (Last Fiscal Year) | -14,318,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 19 |
| Price to Sales (Trailing Twelve Months) | 19 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 22 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 22 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | 0.00% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 7 |
| Price to Book (Most Recent Quarter) | 7 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 82 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -37,338,000 |
| Free Cash Flow (Trailing Twelve Months) | -37,338,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 9 |
| Total Debt to Equity (Most Recent Quarter) | 91 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -40.00% |
| Return on Assets (Trailing Twelve Months) | -40.00% |
| Return on Assets (5 Year) | -24.81% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -83.54% |
| Return on Equity (Trailing Twelve Months) | -83.54% |
| Return on Equity (5 Year) | -44.79% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -50.27% |
| Return on Investment (Trailing Twelve Months) | -50.27% |
| Return on Investment (5 Year) | -29.79% |